Drug Repurposing from an Academic Perspective.

@article{Oprea2011DrugRF,
  title={Drug Repurposing from an Academic Perspective.},
  author={Tudor I. Oprea and Julie E. Bauman and Cristian G. Bologa and Tione Buranda and Alexandre Chigaev and Bruce S. Edwards and Jonathan W. Jarvik and Hattie Gresham and Mark K. Haynes and Brian L. Hjelle and Robert Hromas and Laurie G. Hudson and Debra A. Mackenzie and Carolyn Y. Muller and John C. Reed and Peter C. Simons and Yelena Smagley and J. Jacob Strouse and Zurab Surviladze and Todd A. Thompson and Oleg Ursu and Anna Waller and Angela Wandinger-Ness and Stuart S. Winter and Yang Wu and Susan M. Young and Richard S. Larson and Cheryl Willman and Larry A. Sklar},
  journal={Drug discovery today. Therapeutic strategies},
  year={2011},
  volume={8 3-4},
  pages={
          61-69
        }
}

Tables from this paper

Drug repurposing from the perspective of pharmaceutical companies
TLDR
Some of the main approaches to systematic repurposing are described and the various players in this field are discussed and the need for strategic collaborations to increase the likelihood of success in bringing existing molecules to new indications is discussed.
ROLE OF DRUG REPURPOSING IN CURRENT TREATMENT STRATEGIES AGAINST COVID-19; SYSTEMIC REVIEW
TLDR
This present review is trying to shedding light on the numerous previously well reported and recognized drug which can be mostly used as repurposed medicament in the management of COVID-19 pandemic.
Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics
TLDR
This report provides a high-level overview of how drug developers pursuing repurposed assets have previously navigated funding efforts, regulatory affairs, and intellectual property laws to commercialize these “new” medicines in oncology.
Drug Repurposing: Far Beyond New Targets for Old Drugs
TLDR
This approach is of interest primarily because the authors continue to face significant gaps in the drug–target interactions matrix and to accumulate safety and efficacy data during clinical studies.
Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: regulatory implications
TLDR
Evaluating the regulatory path associated with each type of repurposing strategy according to the previously proposed nomenclature confirmed that repositioning strategies were usually filed under a more complex regulatory process than reformulations.
Off-Patent Drug Repositioning
TLDR
Given the intellectual property landscape, and in the absence of specific property rights, it is suggested that drugs should be prioritized as follows to improve the repositioning strategy: i) OFP, ii) OFM, and iii) ONP, respectively.
Computational and Practical Aspects of Drug Repositioning.
TLDR
A classification scheme-drug repositioning evidence level (DREL)-for all drug reppositioning projects, according to the level of scientific evidence is proposed, which ranges from zero, which refers to predictions that lack any experimental support, to four, which referring to drugs approved for the new indication.
Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target
TLDR
It is argued that drug repurposing is an important approach in modern drug development for cancer therapeutics and the rationale behind this approach together with key barriers and opportunities in cancer drug development are summarized.
...
...

References

SHOWING 1-10 OF 61 REFERENCES
Nonprofit disease groups earmark grants for drug repositioning
TLDR
This approach that the MJFF is trying to apply with the RFA allows clinical investigators to establish high-throughput screens that scan all known drugs against their molecular targets of interest,” says UNM’s Richard Larson, who oversees the CTSA award.
The prince and the pauper. A tale of anticancer targeted agents
TLDR
Examples of known drugs whose potential anticancer activities have been highlighted are provided to encourage further research on these known drugs as a means to foster their translation into clinical trials utilizing the more limited public-sector resources.
Finding New Tricks For Old Drugs: An Efficient Route For Public-Sector Drug Discovery
TLDR
This approach has rapidly identified candidate medications suitable for clinical trials in disorders such as progressive multifocal leukoencephalopathy and amyotrophic lateral sclerosis and led to the discovery of the molecular targets responsible for serious drug side effects, thereby allowing efficient 'counter-screening' to avoid these side effects.
The NCGC Pharmaceutical Collection: A Comprehensive Resource of Clinically Approved Drugs Enabling Repurposing and Chemical Genomics
TLDR
The creation of a definitive, complete, and nonredundant list of all approved molecular entities as a freely available electronic resource and a physical collection of small molecules amenable to high-throughput screening is reported here.
Exploiting drug-disease relationships for computational drug repositioning
TLDR
In this review, it is shown that computational methods for drug repositioning can be classified in two axes: drug based, where discovery initiates from the chemical perspective, or disease based,where discovery begins from the clinical perspective of disease or its pathology.
High-Throughput Screening for Daunorubicin-Mediated Drug Resistance Identifies Mometasone Furoate as a Novel ABCB1-Reversal Agent
TLDR
The authors developed a T-lineage acute lymphoblastic leukemia (T-ALL) cell line that overexpresses ABCB1 and exhibits MDR to daunorubicin (DNR), prednisolone, and vincristine and developed a flow cytometry-based, high-throughput screening (HTS) assay that quantifiesABCB1 efflux.
Identify drug repurposing candidates by mining the Protein Data Bank
TLDR
This work illustrates that by mining the PDB for proteins sharing similarities with the hinge region of protein kinases, this approach can be applied to the detection of druggable sites from 3D structures and is illustrated with detection of the protein kinase hinge motif in the HIV-RT non-nucleosidic allosteric site.
Drug repositioning: identifying and developing new uses for existing drugs
TLDR
Repositioning existing drugs for new indications could deliver the productivity increases that the industry needs while shifting the locus of production to biotechnology companies.
Privileged structures: applications in drug discovery.
TLDR
The identification of privileged structures will be discussed, emphasizing the importance of understanding the structure-target relationships that confer "privileged" status, which allows privileged structure based libraries to be targeted at distinct target families (e.g. GPCRs, LGIC, enzymes/kinases).
PREDICT: a method for inferring novel drug indications with application to personalized medicine
TLDR
A novel method for the large‐scale prediction of drug indications (PREDICT) that can handle both approved drugs and novel molecules and lays the computational foundation for future personalized drug treatments, where gene expression signatures from individual patients would replace the disease‐specific signatures.
...
...